In regards to CHF if they want to add value to their product pipeline, pricing and weight of proof to the submission to the FDA I would get this out ASAP hence next week.
In regards to Chronic back pain we can wait a little and have this as consolidation news since we already have Grunenthal as a partner.
Ann: COVID-19/GVHD Update, Quarterly Report and Appendix 4C, page-120
-
- There are more pages in this discussion • 129 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
0.005(0.39%) |
Mkt cap ! $1.467B | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.31 | $1.27 | $1.653M | 1.285M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16781 | $1.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 9777 | 1 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |